Business Context and Reporting Period
Company: InflaRx N.V.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: InflaRx is a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system (C5a and C5aR). The company's pipeline includes izicopan (oral C5aR inhibitor), vilobelimab (IV anti-C5a antibody, marketed as GOHIBIC), and IFX002 (next-gen anti-C5a antibody).
Strategic Shift: In late 2025 and early 2026, the company announced a strategic realignment to prioritize the clinical development of izicopan (Phase 2b readiness in Hidradenitis Suppurativa) while significantly reducing commercial activities for GOHIBIC (vilobelimab) in the U.S. and Europe due to limited commercial success.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (€) | 2024 (€) | Change |
|---|---|---|---|
| Revenues | 29,331 | 165,789 | (82%) |
| Cost of Sales | (7,267,618) | (3,317,039) | +119% (Increase) |
| Gross Profit | (7,238,287) | (3,151,250) | (130%) |
| Operating Loss | (48,259,420) | (53,008,864) | 9% Improvement |
| Net Loss | (45,633,780) | (46,064,402) | 1% Improvement |
| Cash & Equivalents | 16,022,171 | 18,375,979 | (13%) |
| Marketable Securities | 30,211,169 | 33,969,390 | (11%) |
| Total Liquidity | 46,233,340 | 52,345,369 | (12%) |
| Accumulated Deficit | (377,826,001) | (332,192,221) | 14% Increase |
Note: All figures in Euros (€). Cost of sales increased significantly due to a full inventory write-down of GOHIBIC.
Material Changes vs. Prior Period
- Revenue Decline: Product sales revenue dropped to €29k from €166k in 2024, reflecting the winding down of U.S. commercialization efforts for GOHIBIC.
- Inventory Write-Down: Cost of sales surged by €4.0 million, driven primarily by a €7.3 million write-down of GOHIBIC inventory following the decision to discontinue active sales activities in the U.S.
- R&D Expense Reduction: Research and development expenses decreased by €9.6 million (27%) to €25.7 million, attributed to lower third-party costs for manufacturing and clinical trials.
- Marketing & Sales Reduction: Marketing and sales expenses decreased by €2.3 million (34%) to €4.5 million due to workforce reductions and termination of third-party distribution contracts.
- Government Grants: Other income decreased by €2.6 million to €2.7 million, reflecting a lower recognition of the German Research Allowance (€2.6M in 2025 vs. €5.1M in 2024).
- Foreign Exchange Impact: Net financial results decreased by €4.3 million, largely due to a €8.5 million swing in foreign exchange results caused by the weakening of the U.S. dollar against the Euro.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Strategic Focus: The company is pivoting resources to advance izicopan toward Phase 2b readiness in Hidradenitis Suppurativa (HS) and evaluating development options in Chronic Spontaneous Urticaria (CSU).
- Commercialization: Active commercialization of GOHIBIC in the U.S. has ceased. The product remains available for ordering under Emergency Use Authorization (EUA) on a reactive basis. The company is seeking commercial partners for GOHIBIC in the U.S. and Europe.
- Liquidity Runway: Management believes existing cash, cash equivalents, and marketable securities (approx. €46.2 million) are sufficient to fund operations for at least the next 12 months (into mid-2027), assuming the current cost structure and business plan.
- Capital Needs: Substantial additional funding will be required to complete Phase 2b trials for izicopan and pursue further development. The company plans to raise capital through equity offerings, debt, or strategic collaborations.
Key Risks & Contingencies
- Going Concern Uncertainty: The auditors (KPMG) have highlighted a material uncertainty regarding the company's ability to continue as a going concern due to significant operating losses and the need for substantial funding to advance clinical trials.
- Regulatory Risks: GOHIBIC's EUA in the U.S. and marketing authorization in Europe are subject to ongoing regulatory oversight and potential revocation if conditions change or safety issues arise.
- Manufacturing Dependence: The company relies on third-party manufacturers, including a facility in China, for the supply of vilobelimab, creating supply chain and geopolitical risks.
- Listing Compliance: The company received notice from Nasdaq in March 2026 regarding non-compliance with the Minimum Bid Price Rule (stock price below $1.00 for 30 consecutive days). It has 180 days to regain compliance or risk delisting.
- PFIC Status: The company believes it was a Passive Foreign Investment Company (PFIC) for U.S. tax purposes in 2025, which could result in adverse tax consequences for U.S. investors.
Investor Verification Checklist
- Cash Runway Validation: Verify the sufficiency of the €46.2 million liquidity position against the projected costs of the izicopan Phase 2b trial and ongoing operational expenses.
- Partnership Progress: Monitor announcements regarding potential commercial partnerships for GOHIBIC and development collaborations for izicopan, as internal funding may be insufficient for full commercialization.
- Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 minimum bid price requirement within the 180-day compliance period to avoid delisting.
- Inventory Write-Off Finality: Confirm that the €7.3 million inventory write-down is complete and that no further significant write-downs are anticipated for GOHIBIC.
- Regulatory Status of GOHIBIC: Monitor FDA and EMA communications regarding the status of the EUA and marketing authorization for vilobelimab, particularly regarding the "Just Breathe" platform study obligations.
- Capital Raise Terms: If a new equity offering is announced, review the dilution impact and pricing relative to the current market price.